ArticleAmerican journal of clinical and experimental immunology2012
The role of sphingosine 1-phosphate in immunity and sepsis.
Article in American journal of clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Regulatory role of S1P and its receptors in sepsis-induced liver injury.Frontiers in immunology · 2025Review
- AUF-1 knockdown in mice undermines gut microbial butyrate-driven hypocholesterolemia through AUF-1-Dicer-1-mir-122 hierarchy.Frontiers in cellular and infection microbiology · 2022Article
- The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice.International journal of nephrology and renovascular disease · 2022Article
- Plasma as a resuscitation fluid for volume-depleted shock: Potential benefits and risks.Transfusion · 2021Review
- S1PR1-Associated Molecular Signature Predicts Survival in Patients with Sepsis.Shock (Augusta, Ga.) · 2020Article
- Effects of aged stored autologous red blood cells on human plasma metabolome.Blood advances · 2019Article
- Loss of sphingosine 1-phosphate (S1P) in septic shock is predominantly caused by decreased levels of high-density lipoproteins (HDL).Journal of intensive care · 2019Article
- IntravascularFrontiers in immunology · 2018Article
- Myeloperoxidase-derived 2-chlorofatty acids contribute to human sepsis mortality via acute respiratory distress syndrome.JCI insight · 2017Article
- Activation of ATP secretion via volume-regulated anion channels by sphingosine-1-phosphate in RAW macrophages.Pflugers Archiv : European journal of physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingosine 1-phosphate (S1P) is a lipid metabolite with intra- and extracellular signalling properties. It activates five G protein-coupled cell surface receptors designated S1P-receptors type 1-5 (S1P1-5) that transmit extracellular signals into cells, and it modulates intracellular signalling as a cofactor. The analysis of sphingosine kinases (SphK) type 1 and 2, the key enzymes for S1P production, in different infection models point to an important role for the activation of different immune cells like macrophages, mast cells, and dendritic cells. S1P additionally influences local and systemic lymphocyte circulation and positioning, the vascular tone, and blood pressure. Modulation of S1P-mediated signalling pathways therefore results either in local immune cell activation or systemic immune suppression, or both. Pharmacological approaches that modulate certain S1P-mediated signalling pathways while leaving others untouched appear to be promising new avenues for next generation pharmaceuticals. This review summarizes current strategies to modulate S1P signalling for immune intervention with the clear focus on the specificity of the different principles applied. Known local and systemic effects of S1P on immunity are discussed as potential pharmaceutical targets to combat immune and autoimmune diseases and sepsis.
Indexed as
Identifiers
23885318PMC3714198W88659276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.